D.E. Shaw & Co’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.6M | Sell |
530,698
-123,176
| -19% | -$5.22M | 0.01% | 1239 |
|
|
2025
Q4 | $30.3M | Buy |
653,874
+264,099
| +68% | +$11M | 0.02% | 987 |
|
|
2025
Q3 | $13.6M | Buy |
389,775
+185,850
| +91% | +$6.46M | 0.01% | 1437 |
|
|
2025
Q2 | $6.03M | Sell |
203,925
-57,207
| -22% | -$1.63M | ﹤0.01% | 1885 |
|
|
2025
Q1 | $7.79M | Buy |
261,132
+43,319
| +20% | +$1.32M | 0.01% | 1574 |
|
|
2024
Q4 | $6.24M | Sell |
217,813
-47,789
| -18% | -$1.58M | ﹤0.01% | 1810 |
|
|
2024
Q3 | $10.3M | Buy |
265,602
+66,739
| +34% | +$2.38M | 0.01% | 1414 |
|
|
2024
Q2 | $6.4M | Sell |
198,863
-286
| -0.1% | -$9.92K | 0.01% | 1666 |
|
|
2024
Q1 | $7.73M | Sell |
199,149
-22,356
| -10% | -$782K | 0.01% | 1558 |
|
|
2023
Q4 | $6.82M | Buy |
221,505
+76,353
| +53% | +$1.91M | 0.01% | 1655 |
|
|
2023
Q3 | $3.24M | Buy |
145,152
+33,505
| +30% | +$764K | ﹤0.01% | 2196 |
|
|
2023
Q2 | $2.4M | Sell |
111,647
-33,048
| -23% | -$750K | ﹤0.01% | 2480 |
|
|
2023
Q1 | $3.47M | Buy |
144,695
+120,621
| +501% | +$3.2M | ﹤0.01% | 2255 |
|
|
2022
Q4 | $559K | Buy |
24,074
+1,510
| +7% | +$30.4K | ﹤0.01% | 3793 |
|
|
2022
Q3 | $361K | Sell |
22,564
-1,804
| -7% | -$31.8K | ﹤0.01% | 4219 |
|
|
2022
Q2 | $432K | Sell |
24,368
-106,596
| -81% | -$1.79M | ﹤0.01% | 4180 |
|
|
2022
Q1 | $2.67M | Buy |
130,964
+11,659
| +10% | +$220K | ﹤0.01% | 3019 |
|
|
2021
Q4 | $2.23M | Buy |
119,305
+73,226
| +159% | +$1.43M | ﹤0.01% | 3260 |
|
|
2021
Q3 | $910K | Buy |
+46,079
| New | +$996K | ﹤0.01% | 3678 |
|
|
2020
Q1 | – | Sell |
-53,749
| Closed | -$1.11M | – | 3963 |
|
|
2019
Q4 | $1.11M | Buy |
53,749
+5,823
| +12% | +$97.1K | ﹤0.01% | 2908 |
|
|
2019
Q3 | $550K | Buy |
47,926
+29,990
| +167% | +$342K | ﹤0.01% | 3172 |
|
|
2019
Q2 | $236K | Sell |
17,936
-119,081
| -87% | -$1.59M | ﹤0.01% | 3403 |
|
|
2019
Q1 | $2.07M | Buy |
+137,017
| New | +$2.19M | ﹤0.01% | 2139 |
|
|
2018
Q3 | – | Sell |
-29,455
| Closed | -$703K | – | 3751 |
|
|
2018
Q2 | $703K | Sell |
29,455
-80,517
| -73% | -$1.98M | ﹤0.01% | 2905 |
|
|
2018
Q1 | $2.81M | Sell |
109,972
-117,300
| -52% | -$2.79M | ﹤0.01% | 1802 |
|
|
2017
Q4 | $4.2M | Buy |
227,272
+78,017
| +52% | +$1.12M | 0.01% | 1614 |
|
|
2017
Q3 | $1.57M | Buy |
149,255
+245
| +0.2% | +$2.7K | ﹤0.01% | 2205 |
|
|
2017
Q2 | $1.86M | Buy |
149,010
+5,527
| +4% | +$54.6K | ﹤0.01% | 2020 |
|
|
2017
Q1 | $1.44M | Buy |
+143,483
| New | +$2.13M | ﹤0.01% | 2060 |
|
|
2016
Q2 | – | Sell |
-19,383
| Closed | -$352K | – | 3352 |
|
|
2016
Q1 | $352K | Buy |
19,383
+9,579
| +98% | +$174K | ﹤0.01% | 2957 |
|
|
2015
Q4 | $270K | Buy |
+9,804
| New | +$207K | ﹤0.01% | 3428 |
|
Other funds holding COLL
EAM
VCM
D.E. Shaw & Co's COLL Position: Q1 2026 in Review
D.E. Shaw & Co reduced its Collegium Pharmaceutical (COLL) stake by 19% in Q1 2026, selling an estimated $5.22M and leaving 530,698 shares worth $17.6M. The position accounts for 0.01% of the portfolio, ranked #1239.
D.E. Shaw & Co first reported a position in COLL in Q4 2015 and has held it in 31 quarters since. The position peaked at $30.3M in Q4 2025. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.
- D.E. Shaw & Co held 530,698 shares of Collegium Pharmaceutical worth $17.6M as of Q1 2026.
- D.E. Shaw & Co sold 123,176 Collegium Pharmaceutical shares in Q1 2026, an estimated $5.22M.
- Collegium Pharmaceutical made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1239 holding.
- D.E. Shaw & Co first reported a position in Collegium Pharmaceutical in Q4 2015 and has held it in 31 quarters since.
- D.E. Shaw & Co's Collegium Pharmaceutical position peaked at $30.3M in Q4 2025.
- 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.